Healios K.K. (OTCMKTS:HLOSF – Get Rating) is one of 366 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Healios K.K. to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, dividends, institutional ownership and earnings.
Profitability
This table compares Healios K.K. and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Healios K.K. | N/A | N/A | N/A |
| Healios K.K. Competitors | -623.50% | -59.38% | -21.79% |
Institutional & Insider Ownership
20.3% of Healios K.K. shares are held by institutional investors. Comparatively, 25.6% of shares of all “Biotechnology” companies are held by institutional investors. 25.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Healios K.K. | 0 | 0 | 0 | 0 | N/A |
| Healios K.K. Competitors | 549 | 1730 | 4520 | 43 | 2.59 |
As a group, “Biotechnology” companies have a potential upside of 91.62%. Given Healios K.K.’s peers higher probable upside, analysts plainly believe Healios K.K. has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares Healios K.K. and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Healios K.K. | N/A | N/A | -32.57 |
| Healios K.K. Competitors | $196.50 million | $5.60 million | 24.00 |
Healios K.K.’s peers have higher revenue and earnings than Healios K.K.. Healios K.K. is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Healios K.K. peers beat Healios K.K. on 5 of the 8 factors compared.
Healios K.K. Company Profile
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
